haloperidol has been researched along with Degenerative Diseases, Central Nervous System in 5 studies
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Schizophrenia is a neurodevelopmental disorder associated with persistent symptomatology, severe functional disability, and residual morbidity characteristic of neurodegenerative brain diseases." | 1.34 | Neuroprotection: a therapeutic strategy to prevent deterioration associated with schizophrenia. ( Jarskog, LF; Lieberman, JA; Perkins, DO, 2007) |
| "In the histopathology of Alzheimer's disease (AD) many signs of oxidative reactions can be found building the basis of the oxidative stress hypothesis of AD." | 1.30 | Vitamin E and other antioxidants in neuroprotection. ( Behl, C, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Górska, A | 1 |
| Marszałł, M | 1 |
| Sloderbach, A | 1 |
| Lieberman, JA | 1 |
| Perkins, DO | 1 |
| Jarskog, LF | 1 |
| Harvey, BH | 1 |
| Joubert, C | 1 |
| du Preez, JL | 1 |
| Berk, M | 1 |
| Colado, MI | 1 |
| O'Shea, E | 1 |
| Granados, R | 1 |
| Esteban, B | 1 |
| Martín, AB | 1 |
| Green, AR | 1 |
| Behl, C | 1 |
1 review available for haloperidol and Degenerative Diseases, Central Nervous System
| Article | Year |
|---|---|
[The neurotoxicity of pyridinium metabolites of haloperidol].
Topics: Antipsychotic Agents; Biotransformation; Brain; Delirium; Haloperidol; Humans; Nausea; Neurodegenera | 2015 |
4 other studies available for haloperidol and Degenerative Diseases, Central Nervous System
| Article | Year |
|---|---|
Neuroprotection: a therapeutic strategy to prevent deterioration associated with schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Atrophy; Benzodiazepines; Cerebral Cortex; Child; Cognition | 2007 |
Effect of chronic N-acetyl cysteine administration on oxidative status in the presence and absence of induced oxidative stress in rat striatum.
Topics: Acetylcysteine; Animals; Antipsychotic Agents; Dose-Response Relationship, Drug; Free Radical Scaven | 2008 |
Studies on the role of dopamine in the degeneration of 5-HT nerve endings in the brain of Dark Agouti rats following 3,4-methylenedioxymethamphetamine (MDMA or 'ecstasy') administration.
Topics: Animals; Body Temperature; Brain; Dopamine; Free Radicals; Haloperidol; Levodopa; Male; N-Methyl-3,4 | 1999 |
Vitamin E and other antioxidants in neuroprotection.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Antipsychotic Agents; Estrogens; Female; Fre | 1999 |